Nanotechnology-based combinatorial anti-glioblastoma therapies: moving from terminal to treatable
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therape...
Main Authors: | Barzegar Behrooz, Amir, Talaie, Zahra, Syahir, Amir |
---|---|
Format: | Article |
Published: |
Multidisciplinary Digital Publishing Institute
2022
|
Similar Items
-
Nanotechnology-Based Combinatorial Anti-Glioblastoma Therapies: Moving from Terminal to Treatable
by: Amir Barzegar Behrooz, et al.
Published: (2022-08-01) -
Could we address the interplay between CD133, Wnt/β-Catenin, and TERT signaling pathways as a potential target for Glioblastoma therapy?
by: Behrooz, Amir Barzegar, et al.
Published: (2021) -
Understanding Glioblastoma Biomarkers: Knocking a Mountain with a Hammer
by: Malak Hassn Mesrati, et al.
Published: (2020-05-01) -
Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma
by: Amir Barzegar Behrooz, et al.
Published: (2022-01-01) -
Understanding glioblastoma biomarkers: knocking a mountain with a hammer
by: Mesrati, Malak Hassn, et al.
Published: (2020)